Conformis, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
24 July 2020 - 7:00AM
Conformis, Inc. (NASDAQ:CFMS) announced today that management will
present at the Canaccord Genuity 40th Annual Growth Conference. The
event is being held virtually and will take place between August 11
and 13, 2020. For more information, please
visit
https://www.canaccordgenuity.com/capital-markets/about-us/events.
Webcasted Presentation
Event: |
Canaccord
Genuity 40th Annual Growth Conference |
Date: |
Wednesday, August 12, 2020 |
Time: |
11:30 a.m. to 11:55 a.m. ET |
The live webcast of the presentation will be available by
visiting the Company’s Investor Relations website at
http://ir.conformis.com/events on Wednesday, August 12, 2020.
The webcast will be available for replay on the Company’s website
following the event.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit Image-to-Implant technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient’s unique anatomy. Conformis offers a
broad line of sterile, personalized knee and hip implants and
single-use instruments delivered to hospitals and ambulatory
surgical centers. In clinical
studies, Conformis iTotal CR knee replacement system
demonstrated superior clinical outcomes, including better function
and greater patient satisfaction, compared to traditional,
off-the-shelf implants. Conformis owns or exclusively
in-licenses issued patents and pending patent applications that
cover personalized implants and patient-specific instrumentation
for all major joints.
For more information, visit www.conformis.com. To receive future
releases in e-mail alerts, sign up at ir.conformis.com.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the anticipated
timing of our product launches, and our financial position and
results, total revenue, product revenue, gross margin, operations
and growth, as well as other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” or “would” and similar
expressions, constitute forward-looking statements within the
meaning of the safe harbor provisions of The Private Securities
Litigation Reform Act of 1995. We may not actually achieve
the forecasts disclosed in our forward-looking statements, and you
should not place undue reliance on our forward-looking
statements. Actual financial results could differ materially
from the projections disclosed in the forward-looking statements we
make as a result of a variety of risks and uncertainties, including
risks related to our estimates and expectations regarding our
revenue, gross margin, expenses, revenue growth and other results
of operations, and the other risks and uncertainties described in
the “Risk Factors” sections of our public filings with
the Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
our views as of the date hereof. We anticipate that
subsequent events and developments may cause our views to
change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date
hereof.
Contact
Investor Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2024 to May 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From May 2023 to May 2024